http://www.smarteranalyst.com/2016/07/22/fbr-slashes-price-target-galena-biopharma-inc-gale-reiterates-positive-stance/ recaps some of the saleint assets, not counting un-blidning review of P3 Newvax and possible sale/ merger with Roche, etc. Just the known facts. The possibilities...???